TOKAI Corp.

TSE:9729 Stock Report

Market Cap: JP¥75.1b

TOKAI Valuation

Is 9729 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9729 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 9729 (¥2214) is trading below our estimate of fair value (¥4499.48)

Significantly Below Fair Value: 9729 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9729?

Key metric: As 9729 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 9729. This is calculated by dividing 9729's market cap by their current earnings.
What is 9729's PE Ratio?
PE Ratio12x
EarningsJP¥6.23b
Market CapJP¥75.08b

Price to Earnings Ratio vs Peers

How does 9729's PE Ratio compare to its peers?

The above table shows the PE ratio for 9729 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.4x
3151 Vital KSK Holdings
9.7xn/aJP¥57.3b
3540 C.I. MedicalLtd
8.7x-10.1%JP¥51.1b
3183 WIN-Partners
17.8xn/aJP¥35.0b
7476 AS ONE
25.3x8.2%JP¥202.5b
9729 TOKAI
12x3.7%JP¥75.1b

Price-To-Earnings vs Peers: 9729 is good value based on its Price-To-Earnings Ratio (12x) compared to the peer average (15.4x).

Price to Earnings Ratio vs Industry

How does 9729's PE Ratio compare vs other companies in the JP Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
9729 12.0xIndustry Avg. 14.2xNo. of Companies9PE0816243240+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 9729 is good value based on its Price-To-Earnings Ratio (12x) compared to the JP Healthcare industry average (14.2x).

Price to Earnings Ratio vs Fair Ratio

What is 9729's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9729 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12x
Fair PE Ratio15.4x

Price-To-Earnings vs Fair Ratio: 9729 is good value based on its Price-To-Earnings Ratio (12x) compared to the estimated Fair Price-To-Earnings Ratio (15.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 9729 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥2,214.00
JP¥2,320.00
+4.8%
7.8%JP¥2,500.00JP¥2,140.00n/a2
Nov ’25JP¥2,152.00
JP¥2,320.00
+7.8%
7.8%JP¥2,500.00JP¥2,140.00n/a2
Oct ’25JP¥2,162.00
JP¥2,320.00
+7.3%
7.8%JP¥2,500.00JP¥2,140.00n/a2
Sep ’25JP¥2,279.00
JP¥2,320.00
+1.8%
7.8%JP¥2,500.00JP¥2,140.00n/a2
Aug ’25JP¥2,176.00
JP¥2,320.00
+6.6%
7.8%JP¥2,500.00JP¥2,140.00n/a2
Jul ’25JP¥2,313.00
JP¥2,320.00
+0.3%
7.8%JP¥2,500.00JP¥2,140.00n/a2
Jun ’25JP¥2,099.00
JP¥2,295.00
+9.3%
8.9%JP¥2,500.00JP¥2,090.00n/a2
May ’25JP¥2,111.00
JP¥2,295.00
+8.7%
8.9%JP¥2,500.00JP¥2,090.00n/a2
Apr ’25JP¥2,133.00
JP¥2,295.00
+7.6%
8.9%JP¥2,500.00JP¥2,090.00n/a2
Mar ’25JP¥2,184.00
JP¥2,295.00
+5.1%
8.9%JP¥2,500.00JP¥2,090.00n/a2
Feb ’25JP¥2,143.00
JP¥2,145.00
+0.09%
2.6%JP¥2,200.00JP¥2,090.00n/a2
Jan ’25JP¥2,090.00
JP¥2,145.00
+2.6%
2.6%JP¥2,200.00JP¥2,090.00n/a2
Dec ’24JP¥1,920.00
JP¥2,145.00
+11.7%
2.6%JP¥2,200.00JP¥2,090.00n/a2
Nov ’24JP¥1,919.00
JP¥2,145.00
+11.8%
2.6%JP¥2,200.00JP¥2,090.00JP¥2,152.002
Oct ’24JP¥1,900.00
JP¥2,145.00
+12.9%
2.6%JP¥2,200.00JP¥2,090.00JP¥2,162.002
Sep ’24JP¥1,912.00
JP¥2,145.00
+12.2%
2.6%JP¥2,200.00JP¥2,090.00JP¥2,279.002
Aug ’24JP¥1,913.00
JP¥2,145.00
+12.1%
2.6%JP¥2,200.00JP¥2,090.00JP¥2,176.002
Jul ’24JP¥1,884.00
JP¥2,145.00
+13.9%
2.6%JP¥2,200.00JP¥2,090.00JP¥2,313.002
Jun ’24JP¥1,836.00
JP¥2,220.00
+20.9%
0.9%JP¥2,240.00JP¥2,200.00JP¥2,099.002
Dec ’23JP¥1,879.00
JP¥2,270.00
+20.8%
1.3%JP¥2,300.00JP¥2,240.00JP¥1,920.002
Nov ’23JP¥1,883.00
JP¥2,165.00
+15.0%
6.2%JP¥2,300.00JP¥2,030.00JP¥1,919.002

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

FINDEX

JP¥20.8b

Offers medical systems, office systems, and Healthtech products in Japan.

3649

JP¥812.00

7D

-0.5%

1Y

-12.3%

Charm Care

JP¥39.5b

Engages in nursing care business.

6062

JP¥1,210.00

7D

0.08%

1Y

2.3%

Saint-Care Holding

JP¥18.0b

Provides healthcare services in Japan.

2374

JP¥731.00

7D

1.8%

1Y

-21.1%